About this item:

395 Views | 589 Downloads

Author Notes:

Correspondence: Emilie Alirol, ealirol@dndi.org

Competing interests: We have read the journal’s policy and the authors of this manuscript have the following competing interests: EWH has received grant support/research materials from US Centers for Disease Control and Prevention, National Institutes of Health, Hologic, Becton Dickinson, Cepheid, Roche Molecular, and Cempra; and has acted as a consultant for Astra Zeneca (Entasis), and GlaxoSmithKline.

DAL has provided an external consultancy service for GlaxoSmithKline with respect to gonorrhoea management.

KW has received research funds from Melinta and GlaxoSmithKline.

Subjects:

Research Funding:

The authors received no specific funding for this work.

Keywords:

  • Science & Technology
  • Life Sciences & Biomedicine
  • Medicine, General & Internal
  • General & Internal Medicine
  • IN-VITRO ACTIVITY
  • PENICILLIN-BINDING PROTEIN-2
  • SEXUALLY-TRANSMITTED INFECTIONS
  • MOSAIC-LIKE STRUCTURE
  • NEISSERIA-GONORRHOEAE
  • TREATMENT FAILURE
  • PHARYNGEAL GONORRHEA
  • ANTIMICROBIAL RESISTANCE
  • 500 MG
  • MOLECULAR CHARACTERIZATION
  • Gonorrhea
  • Antimicrobial resistance
  • Antibiotics
  • Drug therapy
  • Drug research and development
  • Neisseria gonorrhoeae
  • Antimicrobials
  • Treatment guidelines

Multidrug-resistant gonorrhea: A research and development roadmap to discover new medicines

Show all authors Show less authors

Tools:

Journal Title:

PLoS Medicine

Volume:

Volume 14, Number 7

Publisher:

, Pages e1002366-e1002366

Type of Work:

Article | Final Publisher PDF

Abstract:

Summary points: 1) The number of gonorrhea cases is rising in many settings worldwide, and an increasing proportion of cases are multidrug-resistant. The choice of antimicrobials that can be used for treatment of gonorrhea is very limited, and resistance has even been reported to extended-spectrum cephalosporins, which are the mainstay of currently recommended antimicrobial therapy. Currently, only 3 new chemical entities are in different stages of clinical development for treatment of gonorrhea. 2) In 2016, the Global Antibiotic Research and Development Partnership (GARDP) was launched by the World Health Organization (WHO) and Drugs for Neglected Disease initiative, which hosts and provides governance for GARDP. 3) GARDP has worked together with experts from different regions to draft “ideal” and “acceptable” Target Product Profiles for the treatment of gonorrhea, reflecting medical need. 4) Amongst other activities to combat antimicrobial resistance, GARDP has developed a plan to meet the urgent need for new drugs to treat gonorrhea. 5) Over the next 7 years, this research and development proposal includes the following: exploring the introduction of a new clinical entity against gonorrhea; the identification of existing, suitable partner drugs; the recovery of previously abandoned, out-of-favor, and withdrawn antibiotics; and the development of simplified treatment guidelines for the empiric management of sexually transmitted infections.

Copyright information:

This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.

This is an Open Access work distributed under the terms of the Creative Commons Universal : Public Domain Dedication License (http://creativecommons.org/publicdomain/zero/1.0/).

Creative Commons License

Export to EndNote